In the second quarter of 2017, there were 967 new licensing deals in the biopharma industry, which was slightly lower than the previous quarter. The number of deals worth over USD 0.5 billion also decreased significantly. The article will highlight the most valuable deals and active deal makers during this period. It will also provide updates on milestone, options, and terminated deals, as well as a preview of the next quarter's licensing activity.